StockData
ImageneBio, Inc. logo

ImageneBio, Inc. (IMA) stock

IMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$3.90+0.70 (+21.87%)

Close on Nov 17, 2026Market cap $44.27MP/E –Yield –

ImageneBio operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

ImageneBio's operating income for the twelve months ending Jun 30, 2026 was -$58.96M. For fiscal 2025 it was -$48.45M. The highest annual figure on record is -$34.14M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$48.45M–
FY2024Dec 31, 2024-$37.00M–
FY2023Dec 31, 2023-$75.42M–
FY2022Dec 31, 2022-$70.90M–
FY2021Dec 31, 2021-$34.14M–
FY2020Dec 31, 2020-$44.52M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$11.78M–
Q1 FY2026Mar 31, 2026-$12.08M–
Q4 FY2025Dec 31, 2025-$8.50M–
Q3 FY2025Sep 30, 2025-$26.59M–
Q2 FY2025Jun 30, 2025-$7.36M–
Q1 FY2025Mar 31, 2025-$6.00M–
Q4 FY2024Dec 31, 2024-$6.14M–
Q3 FY2024Sep 30, 2024-$2.04M–
Q2 FY2024Jun 30, 2024-$15.82M–
Q1 FY2024Mar 31, 2024-$18.23M–
Q4 FY2023Dec 31, 2023-$21.91M–
Q3 FY2023Sep 30, 2023-$19.50M–
Q2 FY2023Jun 30, 2023-$18.49M–
Q1 FY2023Mar 31, 2023-$15.52M–
Q4 FY2022Dec 31, 2022-$15.11M-641.3%
Q3 FY2022Sep 30, 2022-$17.88M–
Q2 FY2022Jun 30, 2022-$20.95M–
Q1 FY2022Mar 31, 2022-$16.96M–
Q4 FY2021Dec 31, 2021$2.79M–
Q3 FY2021Sep 30, 2021-$14.52M–
Q2 FY2021Jun 30, 2021-$12.69M–
Q1 FY2021Mar 31, 2021-$9.72M–
Q4 FY2020Dec 31, 2020-$26.05M–
Q3 FY2020Sep 30, 2020-$6.23M–
Q2 FY2020Jun 30, 2020-$5.06M–
Q1 FY2020Mar 31, 2020-$7.18M–

More ImageneBio figures

See a number that looks wrong?